|
WO2018005374A1
(en)
|
2016-06-27 |
2018-01-04 |
Chemocentryx, Inc. |
Immunomodulator compounds
|
|
KR20190133714A
(ko)
|
2017-03-27 |
2019-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제로서 유용한 치환된 이소퀴놀린 유도체
|
|
US11130740B2
(en)
|
2017-04-25 |
2021-09-28 |
Arbutus Biopharma Corporation |
Substituted 2,3-dihydro-1H-indene analogs and methods using same
|
|
AU2018306619B2
(en)
|
2017-07-28 |
2022-06-02 |
Chemocentryx, Inc. |
Immunomodulator compounds
|
|
CN111225665B
(zh)
|
2017-08-08 |
2023-12-08 |
凯莫森特里克斯股份有限公司 |
大环免疫调节剂
|
|
JP7214752B2
(ja)
|
2018-01-23 |
2023-01-30 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調節剤として有用な２，８－ジアシル－２，８－ジアザスピロ［５．５］ウンデカン化合物
|
|
JP7387616B2
(ja)
|
2018-02-22 |
2023-11-28 |
ケモセントリックス，インコーポレイティド |
Ｐｄ－ｌ１アンタゴニストとしてのインダン－アミン
|
|
US12083118B2
(en)
|
2018-03-29 |
2024-09-10 |
Arbutus Biopharma Corporation |
Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
|
|
US20210236476A1
(en)
*
|
2018-08-29 |
2021-08-05 |
Chemocentryx, Inc. |
Methods of treating cancer with small molecule pd-l1 inhibitors
|
|
CN113891748A
(zh)
|
2019-03-28 |
2022-01-04 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
AU2020276277B2
(en)
|
2019-05-15 |
2025-03-20 |
Chemocentryx, Inc. |
Triaryl compounds for treatment of PD-L1 diseases
|
|
JP2022534967A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
多腫瘍遺伝子シグネチャーおよびその使用
|
|
KR20220016155A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
|
|
EP3977132A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
SG11202112875UA
(en)
|
2019-06-20 |
2021-12-30 |
Chemocentryx Inc |
Compounds for treatment of pd-l1 diseases
|
|
BR112021025888A2
(pt)
|
2019-07-10 |
2022-04-26 |
Chemocentryx Inc |
Indanos como inibidores de pd-l1
|
|
CN112457305B
(zh)
*
|
2019-09-09 |
2025-01-10 |
上海长森药业有限公司 |
含三环结构的芳香杂环化合物，及其制备方法和应用
|
|
CA3153777A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
CN114555080B
(zh)
|
2019-10-16 |
2025-10-10 |
凯莫森特里克斯股份有限公司 |
用于治疗pd-l1疾病的杂芳基联苯胺
|
|
AU2020368393B2
(en)
|
2019-10-16 |
2026-01-08 |
Chemocentryx, Inc. |
Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
|
|
BR112022008191A2
(pt)
|
2019-11-08 |
2022-07-12 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para melanoma
|
|
BR112023003427A2
(pt)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para carcinoma hepatocelular
|
|
AU2021334361A1
(en)
|
2020-08-31 |
2023-05-11 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
WO2022087402A1
(en)
|
2020-10-23 |
2022-04-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
US20240181052A1
(en)
|
2021-03-29 |
2024-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
US20240327389A1
(en)
*
|
2021-05-05 |
2024-10-03 |
Bristol-Myers Squibb Company |
Lactone and lactam containing compounds useful as immunomodulators
|
|
KR20240099362A
(ko)
|
2021-10-29 |
2024-06-28 |
브리스톨-마이어스 스큅 컴퍼니 |
혈액암에 대한 lag-3 길항제 요법
|
|
CA3249004A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Polytherapy for Hepatocellular Carcinoma
|
|
US20230326022A1
(en)
|
2022-04-08 |
2023-10-12 |
Bristol-Myers Squibb Company |
Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
|
|
CN120731228A
(zh)
|
2022-12-21 |
2025-09-30 |
百时美施贵宝公司 |
肺癌的组合疗法
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|